·新华图片精选· 河北河间：瀛州500千伏超高压变电站扩建工程竣工 6月26日，国网河北省电力有限公司工作人员在瀛州500千伏超高压变电站内巡检（无人机照片）。当日，位于河北省河间市境内的瀛州500千伏超高压变电 站扩建工程竣工，标志着河北南部电网迎峰度夏14项主网工程全面完工。 新华社记者 牟宇 摄 贵州黄果树瀑布迎来2025年入汛最大水量 这是6月26日拍摄的贵州黄果树瀑布（无人机照片）。受持续降雨及上游来水影响，位于贵州省安顺市的黄果树瀑布迎来2025年入汛最大水量。据贵州省安 顺市水文水资源局实测数据显示，当日黄果树瀑布流量最高时达每秒528立方米。 02:17 黑龙江垦区："用养结合"保护黑土地 6月24日，黑龙江北大荒农业股份有限公司八五六分公司第六管理区高标准农田的水稻秧苗长势良好（无人机照片）。近年来，黑龙江垦区北大荒集团以保 护黑土耕地、有效提高粮食生产能力为目标，用地与养地相结合，推动农业绿色可持续发展。 新华社发（黄永兴 摄） 新华社发（陈熙 摄） 新华社发（吴德军 摄） 夏季达沃斯论坛|齐聚文化之夜 感受天津魅力 贵州：灾后救援有序进行 6月25日，在贵州省从江县城区，人们在清理街道淤 ...

经济学家迪维尼认为，3.5%的核心军费支出目标"对大多数北约成员国而言非常不现实，许多成员国连 目前2%的标准都难以达到"。 据新华社报道，根据25日发表的北约峰会宣言，北约成员国领导人就未来军费支出目标达成一致，决定 在2035年前将年度国防开支提高至国内生产总值（GDP）的5%。 根据峰会宣言，5%的军费支出目标主要分为两部分：其中3.5%用于核心军费支出，1.5%用于关键基础 设施防护和网络安全等。 谁同意谁反对？ 北约各成员国还同意在2029年对该目标的落实情况进行中期评估，以确保2035年最终实现5%的目标， 这比原定的2032年推迟了3年。 美国总统特朗普声称，美国无须遵守5%的目标，但同时要求其他盟国必须履行义务。他对峰会的结果 表示满意，称在参加北约峰会后对北约的看法"略有不同"，他称赞5%支出目标并承诺 "我们在这里帮助 他们保护他们的国家" 。 尽管北约秘书长吕特称该计划是"一次巨大的飞跃"，但实际上北约内部仍存在分歧。西班牙明确表示， 仅承诺将国防开支提高至国内生产总值的2.1%。 据央视新闻，另有部分成员国对该标准表示担忧，认为实现这一目标存在较大困难。斯洛伐克表示保留 自主决定如何实 ...

6月19日，由《中国证券报》评选的第三届基金投顾金牛奖榜单揭晓，建信基金荣获"基金投顾新锐金牛 奖"，是唯一一家获得该奖项的银行系基金公司。建信基金于2021年获得公募基金投顾业务试点展业资 格，在组合投资管理上积累了较为丰富的实战经验。此外，鉴于在投资者教育方面的创新和长期实践， 建信基金此次还荣获"大学生投教创新金牛奖"。 作为资本市场和资管行业颇具分量的奖项，中国证券报主办的"金牛奖"凭借着对公正、公平、公开、有 公信力原则的严格执行，受到监管层和行业的广泛认可，已成为中国资本市场最具公信力和影响力的权 威奖项之一。第三届基金投顾金牛奖评选在充分调研、核实信息数据的基础上，结合定量和定性两部 分，从顾问服务、投资者获得感、智能科技、业务创新等方面对基金投顾机构进行综合评价。 投前，提供个性化的"产品配置建议"。根据试点期间的展业经验和客户反馈，建信基金开发了"以终为 始"的养老财富管理模型，针对中低风险偏好的客户，从退休年限倒推出最大的含权产品配置比例，通 过对含权资产的配置，实现养老财富增值的目标。投中，通过专业模型引导客户掌握科学的投资节奏。 养老账户的资金流稳定且持续，大部分客户仍然习惯于每年入金 ...

答：公司共承建了三个海绵城市项目，分别为河北迁安项目、 云南玉溪项目、四川遂宁项目，项目涵盖海绵城市全流程规划、 设计、施工及运营。 四、公司海绵城市项目的业务模式及近况？ 1 三、公司与同方投资仲裁案的由来及最新的进展情况。 答：公司与同方投资仲裁案的相关内容均已按照监管规定详 细披露。目前，同方投资仍然不服判决，已向最高人民法院提起 再审申请，现处于再审立案审查阶段，是否符合再审立案条件尚 需最高人民法院审查后裁定。公司已聘请专业的法律团队积极应 对，确保应诉工作有序推进，最大限度降低再审案件对公司的影 响。 证券代码：000068 证券简称：华控赛格 深圳华控赛格股份有限公司 投资者关系活动记录表 编号：2025-01 | 投资者关系活动 | 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 | | --- | --- | | 类别 | □新闻发布会 □路演活动 现场参观 □其他 远东宏信有限公司 翁烨丹 | | | 凯石基金管理有限公司 陈林 | | 参与单位名称及 | 深圳良品私域科技服务有限公司 熊辉 | | 人员姓名 | 深圳源通千相投资有限公司 刘美诺 | | | 深圳创华启盛顾问咨询 ...

Company Overview - Ivanhoe Electric's shares increased by 8.7% to $9.17 in the last trading session, with a notable trading volume, contributing to a 14.7% gain over the past four weeks [1][2] Project Development - The rise in share price follows the completion of the Preliminary Feasibility Study for the Santa Cruz Copper Project in Arizona, marking a significant milestone for securing long-term project financing [2] - The Study emphasizes advanced engineering design from extraction to processing, ensuring the project's bankability and readiness for financing [3] - Construction for the Santa Cruz project is planned to commence in the first half of 2026, aiming for first copper cathode production by 2028 [3] Financial Performance - Ivanhoe Electric is projected to report a quarterly loss of $0.13 per share, reflecting a year-over-year increase of 66.7%, with expected revenues of $0.74 million, up 37% from the previous year [4] - The consensus EPS estimate for the upcoming quarter has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [5] Industry Context - Ivanhoe Electric holds a Zacks Rank of 3 (Hold) within the Zacks Mining - Miscellaneous industry, contrasting with Alpha Metallurgical, which has a Zacks Rank of 5 (Strong Sell) and has seen a 13.3% decline over the past month [6]

Core Viewpoint - Coinbase has been recognized as a leading player in the cryptocurrency sector, with analysts upgrading its price target significantly, reflecting strong growth potential and market position [2][3]. Group 1: Analyst Insights - Bernstein analysts upgraded Coinbase's price target to $510 from $310, maintaining an "Outperform" rating, and described it as the "most misunderstood company" in the crypto space [2]. - Analysts highlighted Coinbase's unique position as the only cryptocurrency company in the S&P 500, its dominance in U.S. crypto trading, and its leadership in the stablecoin exchange market [3]. - Coinbase has diversified its offerings beyond trading, including institutional custody, Base blockchain infrastructure, and a Prime lending desk [3]. Group 2: Price Targets and Broker Ratings - The average price target for Coinbase, based on 26 analysts, is $275.40, indicating a potential decline of 20.13% from its closing price of $344.82 on June 24 [4]. - Coinbase has an average brokerage recommendation (ABR) of 2.14, indicating a shift from an ABR of 2.27 a month ago, with 13 Strong Buy and one Buy recommendations [5][6]. Group 3: Earnings Estimates - The Zacks Consensus earnings estimate for Coinbase's current quarter is $0.91, up from $0.83 a month ago, with the full-year estimate now at $2.96 per share, an increase from $2.41 [7]. Group 4: Market Trends - Coinbase's stock has surged approximately 40% this year, partly due to the Senate's passage of the GENIUS Act, which aims to create a federal framework for stablecoins [8]. - The positive market sentiment is also reflected in the strong gains of other crypto-related companies, indicating increasing institutional adoption of bitcoin and optimism around stablecoin regulation [8]. Group 5: Valuation Concerns - Despite the positive outlook, Coinbase shares are considered to lack value, with a trailing 12-month price-to-earnings (PE) ratio of 49.12X compared to 15.16X for the Financial - Miscellaneous Services industry [9]. Group 6: Investment Options - Investors looking to mitigate risks while capitalizing on Coinbase's momentum may consider COIN-heavy ETFs, which include several funds with at least 10% exposure to Coinbase [10][11].

Core Insights - PayPal has entered into a partnership with the Big Ten and Big 12 conferences to facilitate compensation for student-athletes through its platform [1][3] - This agreement follows a significant court settlement in the House v. NCAA case, which allows schools to compensate student-athletes for the first time, enabling up to $20.5 million in payments to current athletes and $2.8 billion to former players [2] Group 1: Partnership Details - The new agreement allows Big Ten and Big 12 athletic departments to use PayPal exclusively for distributing payments to student-athletes [3] - The initial rollout of this payment system is expected to begin in the summer, coinciding with the effective date of the House settlement on July 1 [3] Group 2: Payment Features - The partnership will enable students at Big Ten and Big 12 universities to receive their compensation quickly and securely, with the option to pay college tuition via PayPal [4] - PayPal aims to become a preferred payment partner at select schools, enhancing the financial experience for student-athletes [4] Group 3: Venmo's Role - PayPal's mobile payment service Venmo is expanding its involvement in college sports, becoming the presenting partner for the first-ever Big Ten Rivalry Series and the official partner of the Big 12 Conference [5][6] - Venmo will also facilitate transactions at college bookstores and for campus athletics, covering items such as tickets, concessions, and merchandise [6] Group 4: Conference Expansion - The Big Ten Conference has expanded to 18 schools, including notable institutions like the University of Maryland and Ohio State University [7] - The Big 12 Conference comprises 16 schools, including Arizona State University and the University of Central Florida [7]

Core Insights - ZyVersa Therapeutics, Inc. has initiated patient recruitment for its VAR 200 Phase 2a clinical study targeting diabetic kidney disease (DKD) [1][2] - VAR 200 is designed to address renal lipotoxicity by removing excess lipids from the kidneys, which is a significant factor in the progression of kidney diseases [3][7] - The study aims to evaluate the efficacy and safety of VAR 200 in patients with type 2 diabetes and DKD, with preliminary data expected in the second half of 2025 [7] Company Overview - ZyVersa is a clinical stage specialty biopharmaceutical company focused on developing first-in-class drugs for renal and inflammatory diseases with significant unmet medical needs [8] - The company is advancing a therapeutic pipeline that includes VAR 200 and another program targeting inflammation [8] Clinical Study Details - The VAR 200 Phase 2a trial will be an open-label study conducted at one to two US sites, enrolling an adequate number of subjects to complete eight [2][7] - The primary efficacy endpoint is the percent change from baseline to week 12 in urinary albumin to creatinine ratio, with treatment lasting 12 weeks followed by a four-week follow-up [2][7] Drug Mechanism and Indications - VAR 200, a Cholesterol Efflux Mediator™, is an injectable drug that aims to reduce renal lipid accumulation, which damages the kidney's filtration system [3][5] - Preclinical studies have shown that VAR 200 can reduce cholesterol and lipid levels, protect against renal injury and fibrosis, and improve proteinuria in various kidney disease models [4][7] Future Prospects - The lead indication for VAR 200 is focal segmental glomerulosclerosis (FSGS), with plans to expand indications based on the results of the ongoing trials [5][7] - The initiation of patient recruitment is considered a key milestone in the development of VAR 200, with the potential to be a first-in-class treatment for kidney disease [7]

新股上市数量、首发募资金额，同比均有所回升，2025年上半年临近结束，A股IPO出现回暖迹象。 A股上半年新股数量及募资金额实现同比增长， Wind数据显示，截至6月26日，A股年内共有51只新股上市，首发募资总额373.55亿元，同比分别增长 约16%、15%。首发市盈率平均值也较去年同期有所下降，新股上市首日平均涨幅则高于去年同期水 平，且上半年新股零破发。 港股则掀起上市热潮 ，"A+H"热度持续攀升。市场预计，港股上半年新股上市数量将达到43只，募资 总额预计达到1067亿港元，募资总额增长超过675%，其中A股上市公司赴港上市的募资总额占比超过 七成。 上半年A股IPO同比小幅回暖 Wind数据显示，截至6月26日，A股已有51只新股上市，相较去年同期的44只，同比增长约16%。 从上市板块分布来看，创业板新股数量居前。51只新股中的20只来自创业板，18只来自沪深主板，7只 来自科创板，6只来自北交所。 相较去年同期，整体募资规模实现小幅增长。上半年已上市的新股，募资总额合计373.55亿元，同比增 长约15%。其中，9只新股募资金额超过10亿元，中策橡胶（603049.SH）首发募资金额最高，达 ...

此时，市场关注的焦点是：创新药行情走到哪里了？究竟是"绝对底部"还是"炒作尾声"？ 据21世纪经济报道记者了解，目前不少基金经理持乐观态度，认为创新药行情还没有走完，但认为当前 创新药存在分化现象，一部分好公司仍在地板价，增长潜力巨大；但一部分垃圾股则存在巨大泡沫，炒 作已至尾声，应谨防踩坑。 创新药基金领涨 今年上半年，重仓创新药的基金表现优异。 21世纪经济报道特约记者 庞华玮 广州报道 近期，创新药板块震荡调整。 截至6月25日，今年以来，港股创新药指数上涨65.50%，万得创新药指数上涨24.83%。 值得一提的是，近两周创新药板块震荡调整期，有资金开始持续买入港股创新药ETF，该基金份额由 91.48亿份增至114.82亿份，增幅高达26%。 此外，从近期一些基金涨跌走势与创新药行情同步来推测，部分主动权益基金可能在二季度创新药上涨 后追高买入创新药，尤其是一批医药基金。 31只重仓创新药的头部基金中，包括19只主动权益基金，6只被动基金，6只QDII基金。 具体来看，今年重仓创新药基金净值涨幅TOP10为：汇添富香港优势精选A（88.98%）、长城医药产业 精选A（76.76%）、永赢医药创新智选 ...